- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Jagsonpal Pharma reported strong Q1 FY27: Revenue +9%, PAT +22%, Op. EBITDA +21%. It acquired 85% of Aequitas Healthcare for ₹20.8 Cr, entering hospital supplies and targeting ₹10 Cr EBITDA post-integration. Cash reserves remain robust at ₹170 Cr despite a ₹40 Cr share buyback.